Ziopharm has reported its financial results for the quarter ended June 30, 2009. The company reported a net loss of $2.4m, or $(0.11) per share, for the second quarter of 2009, as compared to a net loss of $6.5m or $(0.31) per share for the second quarter of 2008.
For the second quarter of 2009, Research and Development expenses declined $3.8m while General and Administrative expenses declined by $0.7m.
The data reveals that the net cash used in operations was $2.2m in the second quarter of 2009, as compared to $6.4m in the same period last year.
Moreover, the decrease in net cash used in operations was primarily attributable to a decrease in net loss from operations of $4.4m. The company ended the June 2009 quarter with cash of approximately $4.5m, which is expected to support operations into the second quarter of 2010.